In vitro intestinal co-culture cell model to evaluate intestinal absorption of Edelfosine lipid nanoparticles

Current Topics in Medicinal Chemistry

Volumn 14, Issue 9, 2014, Pages 1124-1132

  Lasa Saracíbar, Beatriz ^a   Guada, Melissa ^a   Sebastián, Victor ^b,c   Blanco Prieto, Maria J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Caco 2; Edelfosine; Lipid nanoparticles; Permeabiltity; Raji; Transport

Indexed keywords

EDELFOSINE LIPID NANOPARTICLE; NANOPARTICLE; PROTEIN ZO1; UNCLASSIFIED DRUG; VILLIN; DRUG CARRIER; EDELFOSINE; ETHER PHOSPHOLIPID; LIPID;

ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG PENETRATION; DRUG STABILITY; DRUG TRANSPORT; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INTESTINE ABSORPTION; PHARMACOLOGICAL PARAMETERS; POLIDISPERSITY INDEX; ANIMAL; CACO 2 CELL LINE; COCULTURE; CYTOLOGY; INTESTINE CELL; METABOLISM; MOUSE; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; SURFACE PROPERTY; TUMOR CELL CULTURE;

ADMINISTRATION, ORAL; ANIMALS; CACO-2 CELLS; COCULTURE TECHNIQUES; DRUG CARRIERS; ENTEROCYTES; HUMANS; INTESTINAL ABSORPTION; LIPIDS; MICE; NANOPARTICLES; PARTICLE SIZE; PHOSPHOLIPID ETHERS; SURFACE PROPERTIES; TUMOR CELLS, CULTURED;

EID: 84903721128     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666140329225340     Document Type: Article

References (35)

1. van Blitterswijk, W.J.; Verheij, M. Anticancer mechanisms and clinical application of alkylphospholipids. Biochim. Biophys. Acta, 2013, 1831(3), 663-674.
2. Estella-Hermoso de Mendoza, A.; Campanero, M.A.; De la Iglesia-Vicente, J.; Gajate, C; Mollinedo, F.; Blanco-Prieto, M.J. Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosup-pressed mice. Clin. Cancer Res., 2009, 15(3), 858-864.
3. Lasa-Saracibar, B.; Estella-Hermoso de Mendoza, A.; Guada, M.; Dios-Vieitez, C; Blanco-Prieto, M.J. Lipid nanoparticles for cancer therapy: state of the art and future prospects. Expert Opin. Drug Deliv., 2012, 9(10), 1245-1261.
4. Mollinedo, F.; De la Iglesia-Vicente, J.; Gajate, C; Estella-Hermoso de Mendoza, A.; Villa-Pulgarin, J.A.; Campanero, M.A.; Blanco-Prieto, M.J. Lipid raft-targeted therapy in multiple myeloma. Oncogene, 2010, 29(26), 3748-3757.
5. Estella-Hermoso de Mendoza, A.; Rayo, M.; Mollinedo, F.; Blanco-Prieto, M.J. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: development and in vitro characterization. Eur. J. Pharm. Biopharm., 2008, 68(2), 207-213.
6. Sambuy, Y.; De Angelis, I.; Ranaldi, G.; Scarino, M. L.; Stammati, A.; Zucco, F. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol. Toxicol, 2005, 21(1), 1-26.
7. Mabbott, N.A.; Donaldson, D.S.; Ohno, H.; Williams, I.R.; Mahajan, A. Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium. Mucosal Immunol, 2013, 6(4), 666-677.
8. Antunes, F.; Andrade, F.; Araujo, F.; Ferreira, D.; Sarmento, B. Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs. Eur. J. Pharm. Biopharm., 2012, 83(3), 427-435.
9. des Rieux, A.; Fievez, V.; Theate, I.; Mast, J.; Preat, V.; Schneider, Y.J. An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur. J. Pharm. Sci., 2007, 30(5), 380-391.
10. Beloqui, A.; Solinis, M.A.; Gascon, A.R.; del Pozo-Rodriguez, A.; des Rieux, A.; Preat, V. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J. Control. Release, 2012, 166(2), 115-123.
11. Kerneis, S.; Bogdanova, A.; Kraehenbuhl, J.P.; Pringault, E. Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria. Science, 1997, 277(5328), 949.
12. Tynan, W.; Dickerson, J.; Scharf, M.; Cooper, J.; Byrne, D.; Brayden, D.; Higgins, L.; Evans, C; O'Mahony, D.J. Cell culture modeling of specialized tissue: identification of genes expressed specifically by follicle-associated epithelium of Peyer's patch by expression profiling of Caco-2/Raji co-cultures. Int. Immunol, 2004, 16(1), 91-99.
13. Ander Estella-Hermoso de Mendoza, M.J.B.-P., Miguel Angel Campanero, Faustino Mollinedo, Janny Villa-Pulgarín, Rubén Va-rela. Development and use of lipidic nanoparticles loaded with edelfosine and ether phospholipids in antitumoral and antiparasitic therapy. Spain. Patent P201130433, October, 03, 2011.
14. Estella-Hermoso de Mendoza, A.; Campanero, M.A.; Mollinedo, F.; Blanco-Prieto, M.J. Comparative study of A HPLC-MS assay versus an UHPLC-MS/MS for anti-tumoral alkyl lysophospholipid edelfosine determination in both biological samples and in lipid nanoparticulate systems. J. Chromatogr. B Analyt. Technol. Bio-med. Life Sci., 2009, 877(31), 4035-4041.
15. Millicell® ERS-2 User Guide. http://www.millipore.com/user_guides.nsf/a73664f9f981af8c852569b9005b4eee/a5708d8207d7acc f85257609005c7c5f/$FILE/00108103.pdf (Accesed Sept 11, 2013).
16. Pusch, J.; Votteler, M.; Gohler, S.; Engl, J.; Hampel, M.; Walles, H.; Schenke-Layland, K. The physiological performance of a three-dimensional model that mimics the microenvironment of the small intestine. Biomaterials, 2011, 32(30), 7469-7478.
17. Estella-Hermoso deMendoza, A.; Preat, V.; Mollinedo, F.; Blanco-Prieto, M.J. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J. Control. Release, 2011, 156(3), 421-426.
18. Lasa-Saracibar, B.; Estella-Hermoso de Mendoza, A.; Mollinedo, F.; Odero, M.D.; Blanco-Prieto, M.J. Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines. Cancer Lett, 2013, 334(2), 302-310.
19. Gullberg, E.; Leonard, M.; Karlsson, J.; Hopkins, A.M.; Brayden, D.; Baird, A.W.; Artursson, P. Expression of specific markers and particle transport in a new human intestinal M-cell model. Bio-chem. Biophys. Res. Commun., 2000, 279(3), 808-813.
20. Stevenson, B.R.; Siliciano, J.D.; Mooseker, M.S.; Goodenough, D.A. Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J. Cell. Biol, 1986, 103(3), 755-766.
21. Kerneis, S.; Bogdanova, A.; Colucci-Guyon, E.; Kraehenbuhl, J.P.; Pringault, E. Cytosolic distribution of villin in M cells from mouse Peyer's patches correlates with the absence of a brush border. Gastroenterology, 1996, 110(2), 515-521.
22. Weston, S.A.; Parish, C.R. New fluorescent dyes for lymphocyte migration studies. Analysis by flow cytometry and fluorescence microscopy. J. Immunol. Methods, 1990, 133(1), 87-97.
23. Xue, X.; Liang, X.J. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. Chin. J. Cancer, 2012, 31(2), 100-109.
24. Troutman, M.D.; Thakker, D.R. Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells. Pharm. Res., 2003, 20(8), 1192-1199.
25. Roger, E.; Lagarce, F.; Garcion, E.; Benoit, J.P. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J. Control. Release, 2009, 140(2), 174-181.
26. Gajate, C; Mollinedo, F. Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH(3) (edelfosine), a proapoptotic agent in tumor cells. Curr. Drug Metab., 2002, 3(5), 491-525.
27. Wilcox, R.W.; Wykle, R.L.; Schmitt, J.D.; Daniel, L.W. The degradation of platelet-activating factor and related lipids: susceptibility to phospholipases C and D. Lipids, 1987, 22(11), 800-807.
28. Magistrelli, A.; Villa, P.; Benfenati, E.; Modest, E.J.; Salmona, M.; Tacconi, M.T. Fate of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET18-OME) in malignant cells, normal cells, and isolated and perfused rat liver. Drug Metab. Dispos., 1995, 23(1), 113-118.
29. Gaumet, M.; Gurny, R.; Delie, F. Interaction of biodegradable nanoparticles with intestinal cells: the effect of surface hydrophilic-ity. Int. J. Pharm., 2009, 390(1), 45-52.
30. Jang, S.H.; Wientjes, M.G.; Au, J.L. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J. Pharmacol. Exp. Ther., 2001, 298(3), 1236-1242.
31. Danielsen, E.M.; Hansen, G.H. Lipid rafts in epithelial brush borders: atypical membrane microdomains with specialized functions. Biochim. Biophys. Acta, 2003, 1617(1-2), 1-9.
32. Kunding, A.H.; Christensen, S.M.; Danielsen, E.M.; Hansen, G.H. Domains of increased thickness in microvillar membranes of the small intestinal enterocyte. Mol.Membr. Biol, 2010, 27(4-6), 170-177.
33. Ausili, A.; Torrecillas, A.; Aranda, F.J.; Mollinedo, F.; Gajate, C; Corbalan-Garcia, S.; de Godos, A.; Gomez-Fernandez, J.C. Edel-fosine is incorporated into rafts and alters their organization. J. Phys. Chem. B, 2008, 112(37), 11643-11654.
34. Iwao, T.; Toyota, M.; Miyagawa, Y.; Okita, H.; Kiyokawa, N.; Akutsu, H.; Umezawa, A.; Nagata, K.; Matsunaga, T. Differentiation of human induced pluripotent stem cells into functional enterocyte-like cells using a simple method. Drug Metab. Pharmacok., 2013 (http://dx.doi.org/10.2133/dmpk.DMPK-13-RG-005).
35. McCracken K.W.; Howell, J.C; Wells, J.M.; Spence, J.R. Generating human intestinal tissue from pluripotent stem cells in vitro. Nat. Protoc, 2011, 6(12), 1920-1928.